FLT3 and acute myeloid leukemia: We conclude that TET2(+), age, and white blood cell count convey an outcome risk modulation for AML with NPM1mut/FLT3‐ITD(−), as does CD34 and ID‐Ara‐C induction for NPM1mut/FLT3‐ITD(+).